S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
NASDAQ:DARE

Daré Bioscience - DARE Stock Forecast, Price & News

$0.90
+0.01 (+1.12%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.89
▼
$0.93
50-Day Range
$0.89
▼
$1.05
52-Week Range
$0.88
▼
$2.14
Volume
113,747 shs
Average Volume
203,065 shs
Market Capitalization
$76.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Daré Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
900.3% Upside
$9.00 Price Target
Short Interest
Healthy
1.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.28) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

897th out of 1,022 stocks

Pharmaceutical Preparations Industry

442nd out of 499 stocks

See Top Rated MarketRank™ Stocks Here
DARE stock logo

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

December 4, 2022 | americanbankingnews.com
Daré Bioscience (NASDAQ:DARE) Earns Buy Rating from Analysts at Jonestrading
November 15, 2022 | finance.yahoo.com
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
November 15, 2022 | finance.yahoo.com
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
November 14, 2022 | finance.yahoo.com
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
November 11, 2022 | markets.businessinsider.com
H.C. Wainwright Reaffirms Their Buy Rating on Daré Bioscience (DARE)
November 11, 2022 | seekingalpha.com
Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript
November 10, 2022 | finance.yahoo.com
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
November 10, 2022 | finance.yahoo.com
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
November 8, 2022 | finance.yahoo.com
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
November 3, 2022 | msn.com
Dare 2 Care helps fund Leeza’s Care Connection
November 3, 2022 | msn.com
‘Truth or Dare’ Director Alek Keshishian Says Madonna Asked for a Sequel, but ‘We Just Didn’t See Eye to Eye’
November 3, 2022 | finance.yahoo.com
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
November 1, 2022 | finance.yahoo.com
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
October 25, 2022 | benzinga.com
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
October 19, 2022 | msn.com
Fair Oaks man accused of murder in fentanyl death of Auburn woman
October 17, 2022 | finance.yahoo.com
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
October 12, 2022 | msn.com
Swimming advisory lifted at Dare County sound-side site
October 11, 2022 | msn.com
Nexstar Media (NXST) Launches Dare to Love, Defy to Hate
October 10, 2022 | finance.yahoo.com
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
October 9, 2022 | msn.com
Delta 2022: Dare Inaugurates 14 NSF Sub-Committees
October 8, 2022 | nbcnews.com
Black queer Milwaukeeans on Netflix's Jeffrey Dahmer series: 'How dare you?'
October 7, 2022 | msn.com
Dare inaugurates NBBF board
October 3, 2022 | nasdaq.com
Daré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 69% if they invested five years ago
September 30, 2022 | msn.com
Dare County Schools goes virtual Friday because of Ian's possible impacts
September 17, 2022 | marketwatch.com
Dare Bioscience to Participate in Two Upcoming Conferences
See More Headlines
Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings
11/10/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DARE
CUSIP
N/A
CIK
1401914
Web
www.darebioscience.com
Phone
(858) 926-7655
Fax
617-494-1544
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+455.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,700,000.00
Net Margins
N/A
Pretax Margin
-245.47%
Return on Equity
-76.11%
Return on Assets
-47.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.17
Quick Ratio
2.17

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
1.76

Miscellaneous

Outstanding Shares
84,820,000
Free Float
81,432,000
Market Cap
$76.31 million
Optionable
Not Optionable
Beta
1.17

Key Executives

  • Ms. Sabrina Martucci Johnson (Age 55)
    Pres, CEO, Sec. & Director
    Comp: $643.48k
  • Ms. Lisa Walters-Hoffert (Age 63)
    Chief Financial Officer
    Comp: $439.33k
  • Mr. John A. Fair (Age 50)
    Chief Strategy Officer
    Comp: $435.83k
  • Mr. Mark Walters (Age 67)
    VP of Operations
  • Ms. MarDee J. Haring-Layton (Age 46)
    VP of Accounting & Fin.
  • Dr. David Friend
    Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DARE shares.
View DARE analyst ratings or view top-rated stocks.

What is Daré Bioscience's stock price forecast for 2023?

4 brokers have issued 1 year target prices for Daré Bioscience's stock. Their DARE share price forecasts range from $4.00 to $17.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 900.3% from the stock's current price.
View analysts price targets for DARE or view top-rated stocks among Wall Street analysts.

How have DARE shares performed in 2022?

Daré Bioscience's stock was trading at $2.00 at the beginning of 2022. Since then, DARE shares have decreased by 55.0% and is now trading at $0.8997.
View the best growth stocks for 2022 here.

When is Daré Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our DARE earnings forecast.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. During the same quarter in the previous year, the company posted ($0.24) earnings per share.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.17%), Renaissance Technologies LLC (0.77%), Founders Financial Securities LLC (0.41%), Price T Rowe Associates Inc. MD (0.15%), Virtu Financial LLC (0.08%) and UBS Group AG (0.07%).
View institutional ownership trends.

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.90.

How much money does Daré Bioscience make?

Daré Bioscience (NASDAQ:DARE) has a market capitalization of $76.31 million. The biotechnology company earns $-38,700,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 12/9/2022 by MarketBeat.com Staff